Leukemia Clinical Trials

Showing 2621-2640 of 10,987 trials

Phase 2 Study of Dacomitinib in NSCLC

NCT04027647

This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites.

NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more

National Cancer Centre, Singapore118 participantsStarted Sep 2019

Hong Kong, Hong Kong • Kuching, Sarawak, Malaysia • Kuala Lumpur, Malaysia +6 more locations

Not Yet Recruiting

Clonal Hematopoiesis of Immunological Significance

NCT05969821

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Immune System DiseasesAutoimmune DiseasesInflammation+13 more

Assistance Publique - Hôpitaux de Paris1,000 participantsStarted Sep 2025

Phase 2 Study of Dacomitinib in NSCLC

Clonal Hematopoiesis of Immunological Significance

Related Searches

Effects of Integrative Neuromuscular Traning on Physical Fitness and Dribbling Performance Among High School Male Football Players in Shandong, China

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

AVID100 in Advanced Epithelial Carcinomas

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases

Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

The Short-Term and Long-Term Effects of Providing Mechanical Bath in Terminally Ill Patients

Bile Omics for Diagnosing Indeterminate Biliary Strictures

Feasibility of a Life Coping Program: A Study Protocol

In-person and Telehealth Visual Rehabilitation for Children With Low Vision

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Oral-ATO for TP53-mutated Myeloid Malignancies

Comparison of the Clinical Performance of High Strength Hybrid Ceramic Indirect Restorations Cemented on Endodontically Treated Teeth Using Bioactive Versus Conventional Self Adhesive Resin Cements.